Mediastinoscopy vs Endosonography for Mediastinal Nodal Staging of Lung Cancer
A Randomized Trial

Jouke T. Annema, MD, PhD
Jan P. van Meerbeeck, MD, PhD
Robert C. Rintoul, FRCP, PhD
Christophe Dooms, MD, PhD
Ellen Deschepper, PhD
Olaf M. Dekkers, MA, MD, PhD
Paul De Leyn, MD, PhD
Jerry Braun, MD
Nicholas R. Carroll, FRCP, FRCR
Marleen Praet, MD, PhD
Frederick de Ryck, MD
Johan Vansteenkiste, MD, PhD
Frank Vermassen, MD, PhD
Michel I. Versteegh, MD
Maud Veselic, MD
Andrew G. Nicholson, FRCPath, DM
Klaus F. Rabe, MD, PhD
Kurt G. Tournoy, MD, PhD

UNCG CANCER IS THE MOST COMMONLY DIAGNOSED CANCER WORLDWIDE (1.35 MILLION/YEAR) AND ALSO THE MOST FREQUENT CAUSE OF CANCER DEATH (1.18 MILLION/YEAR).1 Clinical staging of lung cancer is an integral part of patient care because it directs therapy and has prognostic value. Imaging with computed tomography (CT) is valuable for assessing the primary tumor (T-stage) while fluorodeoxyglucose positron emission tomography (PET) is valuable for detecting metastases. In cases where the primary tumor is resectable and in the absence of disease is detected, mediastinal nodal staging is recommended for patients with resectable non-small cell lung cancer (NSCLC). Surgical staging has limitations, which results in the performance of unnecessary thoracotomies. Current guidelines acknowledge minimally invasive endosonography followed by surgical staging (if no nodal metastases are found by endosonography) as an alternative to immediate surgical staging.

Objective To compare the 2 recommended lung cancer staging strategies.

Design, Setting, and Patients Randomized controlled multicenter trial (Ghent, Leiden, Leuven, Papworth) conducted between February 2007 and April 2009 in 241 patients with resectable (suspected) NSCLC in whom mediastinal staging was indicated based on computed or positron emission tomography.

Intervention Either surgical staging or endosonography (combined transesophageal and endobronchial ultrasound [EUS-FNA and EBUS-TBNA] followed by surgical staging in case no nodal metastases were found at endosonography. Thoracotomy with lymph node dissection was performed when there was no evidence of mediastinal tumor spread.

Main Outcome Measures The primary outcome was sensitivity for mediastinal nodal (N2/N3) metastases. The reference standard was surgical pathological staging. Secondary outcomes were rates of unnecessary thoracotomy and complications.

Results Two hundred forty-one patients were randomized, 118 to surgical staging and 123 to endosonography, of whom 65 also underwent surgical staging. Nodal metastases were found in 41 patients (35%; 95% confidence interval [CI], 27%-44%) by surgical staging vs 56 patients (46%; 95% CI, 37%-54%) by endosonography (P = .11) and in 62 patients (50%; 95% CI, 42%-59%) by endosonography followed by surgical staging (P = .02). This corresponded to sensitivities of 79% (41/52; 95% CI, 66%-88%) vs 85% (56/66; 95% CI, 74%-92%) (P = .47) and 94% (62/66; 95% CI, 85%-98%) (P = .02). Thoracotomy was unnecessary in 21 patients (18%; 95% CI, 12%-26%) in the mediastinoscopy group vs 9 (7%; 95% CI, 4%-13%) in the endosonography group (P = .02). The complication rate was similar in both groups.

Conclusions Among patients with (suspected) NSCLC, a staging strategy combining endosonography and surgical staging compared with surgical staging alone resulted in greater sensitivity for mediastinal nodal metastases and fewer unnecessary thoracotomies.

Trial Registration clinicaltrials.gov Identifier: NCT00432640

©2010 American Medical Association. All rights reserved.

(Areprinted) JAMA, November 24, 2010—Vol 304, No. 20 2245
sence of distant metastases, mediastinal nodal involvement (N-stage) directs treatment. Surgical resection of the tumor is the treatment of choice in the absence of mediastinal nodal metastases, whereas combined modality treatment is indicated for patients with mediastinal nodal metastases.

To detect mediastinal metastases, patients are routinely investigated with CT and fluorodeoxyglucose PET, followed by mediastinal tissue staging for enlarged or PET-positive intrathoracic nodes, as imaging alone is inaccurate. Mediastinal tissue staging is classically performed by mediastinoscopy, a surgical diagnostic procedure with a sensitivity of approximately 78%.

Undetected mediastinal metastases are a major cause of unnecessary thoracotomies, occurring in 28% of patients. Unnecessary thoracotomies result in suboptimal treatment, significantly impaired functional health status, and avoidable mortality.

Mediastinal lymph nodes can also be sampled under real-time ultrasound control from either the esophagus (transeosophageal ultrasound-guided fine-needle aspiration [EUS-FNA]) or the airways (endobronchial ultrasound-guided transbronchial needle aspiration [EBUS-TBNA]). Combined EUS and EBUS can reach almost all mediastinal nodal stations with a reported sensitivity of 93%. Current lung cancer staging guidelines acknowledge endosonography as a minimally invasive alternative to surgical staging to detect nodal disease, reducing the need for surgical staging in up to two-thirds of patients. At present it is not known whether initial mediastinal tissue staging of lung cancer by endosonography improves the detection of nodal metastases and reduces the rate of unnecessary thoracotomies.

This study was originally planned to examine the hypothesis that minimally invasive combined endoscopic procedures are as good as or even better than surgical staging (mediastinoscopy) for the evaluation of mediastinal lymph nodes in patients with lung cancer. However, since international guidelines regard surgical staging as the gold standard and currently state that endosonography should be followed by surgical staging if no metastases are found by endosonography, we incorporated this diagnostic sequence into the protocol. Therefore, the primary analysis compared surgical staging alone vs endosonography followed by surgical staging, thereby allowing evaluation between these 2 diagnostic strategies. In addition, we compared surgical staging against endosonography alone.

**METHODS**

Patients with potentially resectable non–small cell lung cancer (NSCLC) were eligible if there was an indication for mediastinal nodal sampling according to current guidelines (mediastinal nodes with short axis ≥10 mm or PET-positive mediastinal or hilar nodes or centrally located lung tumor). Patients with proven distant metastasis, irresectable disease (as judged by the thoracic surgeon on the available imaging), or small peripheral lung tumors without evidence of enlarged or PET-positive intrathoracic nodes were not considered for eligibility. Patients also had to be 18 years or older and able to undergo surgical resection of the lung tumor. Prior diagnostic evaluation included conventional workup (medical history, physical examination, laboratory tests, and bronchoscopy), CT, and integrated whole-body PET-CT.

Exclusion criteria were concurrent malignancy; technical contraindication to EUS (eg, esophageal stenosis), EBUS, or surgical staging (eg, prior mediastinoscopy, current tracheostomy); pregnancy; or inability to consent. Candidates for study participation were identified at the weekly multidisciplinary lung oncology meeting of the participating centers and provided written informed consent. This investigator-initiated trial was approved by the ethical committees of the 4 participating hospitals (Leiden University Medical Center, the Netherlands; the University Hospitals of Ghent and Leuven in Belgium; and Papworth Hospital, United Kingdom) and registered as ASTER (Assessment of Surgical Staging vs Endosonographic Ultrasound in Lung Cancer: a Randomized Clinical Trial).

**Study Design**

Patients were randomly assigned (1:1) to either surgical staging alone (surgical staging group, current standard of care) or endosonography (combined EUS-FNA and EBUS-TBNA) followed by surgical staging if no nodal metastases were found at endosonography (endosonography group, novel alternative staging strategy). In the event of pathological proof of mediastinal (N2/N3) metastases or evidence of mediastinal tumor invasion implying irresectability (T4), patients were classified as having locally advanced disease (stage IIIA/B) and were referred for multimodality therapy. For patients without evidence of mediastinal metastases following surgical staging in either study group, a thoracotomy with complete lymph node dissection was performed. Per protocol, study inclusion, preliminary findings, and complications were evaluated 1 year after start of the study.

**Endosonography**

Endosonography of the mediastinum was performed with patients under moderate sedation as previously described. EUS-FNA was performed initially (Pentax 3UX/38UX; Pentax, Tokyo, Japan, or Olympus GF-UCT140-AL5; Olympus, Tokyo) formed initially (Pentax 3UX/38UX; Pentax, Tokyo, Japan, or Olympus GF-UCT140-AL5; Olympus, Tokyo) followed by EBUS-TBNA (Olympus BF-UC160F-OL). A systematic examination of left and right paratracheal, paracarinal, and paraesophageal mediastinal nodes was performed. Nodes that were suspicious on CT, PET, or ultrasound imaging were sampled under real-time ultrasound guidance with 22-gauge needles and labeled according to the Mountain-Dresler map. When the primary lung tumor was visible by endosonography, the presence or absence of direct mediastinal tumor invasion (T4) was recorded. The cytology preparations were analyzed using...
the primary tumor was visible, the presence or absence of mediastinal invasion (T4) was noted. Thoracotomy was performed according to current guidelines in the absence of mediastinal nodal metastasis or direct mediastinal tumor invasion following surgical staging. At the time of lung resection, a systematic lymph node dissection was performed (at least 3 mediastinal stations, including the subcarinal station) according to current guidelines. All hilar and intrapulmonary (N1) lymph nodes were counted as a single station. Histological examination of the resected nodes and resection specimen and pTaN classification was performed according to current guidelines.

End Points

The primary end point was sensitivity for detection of mediastinal nodal (N2/N3) metastases by either staging strategy. Sensitivity was defined as the proportion of patients with N2/N3 disease for whom the diagnostic test was positive. Thoracotomy with nodal dissection was considered the reference standard in both study groups for cases without N2/N3 involvement after mediastinal staging. Because reported false-positive EUS/EBUS findings are rare, it was decided at the time of study design, in conjunction with the ethics committees, that positive EUS/EBUS results would not be verified by surgical staging because this would lead to inappropriate surgery in virtually all of these patients.

Secondary end points were as follows: (1) rate of unnecessary thoracotomies defined as either exploratory thoracotomy, unexpected presence of mediastinal nodal metastases (pN2/N3) or tumor invasion of the mediastinum at thoracotomy (pT4), pM1, thoracotomy for SCLC or benign disease (other than carcinoid or hamartoma), or death within 30 days after surgery; (2) rate of complications due to preoperative staging procedures, defined as persistent (>6 months) hoarseness, pneumothorax, mediastinitis, major bleeding, and necessary conversion to thoracotomy; (3) detection rate of locally advanced disease, defined as mediastinal nodal metastases or tumor invasion (cT4 or cN2/N3); (4) rate of avoided medias- tonal staging because this would lead to inappropriate surgery in virtually all of these patients.

Statistical Analysis

For the primary analysis, sensitivity and negative predicative value (NPV) regarding mediastinal nodal status were calculated on an intention-to-treat basis for all randomized patients. For patients with a missing reference standard, a multiple imputation procedure was used to obtain 100,000 samples from the most likely value for the missing data. Sampling was based on a binomial distribution with estimated probability for positive mediastinal nodes. Median values of simulated distributions are reported. In a secondary (complete case) analysis, sensitivity and NPV were calculated on those patients for whom complete information on mediastinal nodal status was available. Cases for which surgical-pathological verification of negative findings on endosonography or surgical staging were missing were excluded for the aim of this specific analysis. In a third analysis, sensitivity and NPV of surgical staging vs endosonography alone was performed. For this analysis, we also used multiple imputations for the missing data.

A sample size of at least 186 patients was initially calculated to demonstrate a 20% increase in the sensitivity to detect mediastinal nodal metastases (N2/N3) with endosonography followed by surgical staging vs surgical staging alone, assuming a prevalence of mediastinal nodal metastases of 70% and a dropout rate of 5% (power 80%, type I error P<.05, 2-sided testing). However, during a prespecified interim monitoring of the study, the prevalence of mediastinal nodal metastases was found to be 55%, and therefore the sample size was increased to 240 patients. No end point analysis was performed at this time. Randomization of patients between the 2 groups was stratified per hospital using a web-based program.

A $\kappa$ value was calculated to assess the interobserver agreement of both the EUS and the EBUS cytology samples. Fisher exact tests were used for the analysis of categorical data and to compare sensitivity and NPV between study groups. Independent t tests were used to compare groups of continuous, normally distributed variables. Statistical analyses were performed using SPSS 17.0 (SPSS Inc, Chicago, Illin-}
ing (Figure). Both groups were well balanced for all major clinical characteristics (Table 1).

Surgical Staging Alone
Surgical staging was performed in 117 patients because a distant metastasis was found in 1 patient before the surgical staging procedure. One hundred sixteen patients underwent cervical mediastinoscopy, which was combined with a parasternal mediastinotomy in 3 and a thoracotomy in 2 patients. One patient underwent a thoracotomy only. A median of 4 mediastinal nodal stations (range, 0-5) were sampled at surgical staging. Mediastinal metastases were found in 41 of 118 patients (35%; 95% CI, 27%-44%). In 4 patients (1 without nodal metastases), direct mediastinal invasion by the lung tumor was found. In the 75 patients without locally advanced disease, thoracotomy was performed in 70 patients, showing nodal metastases in 10 (of whom 2 also had mediastinal tumor invasion) and mediastinal invasion alone in 6 patients (Figure).

Endosonography Followed by Surgical Staging
Endosonography was performed in 123 patients and detected mediastinal nodal metastases in 56 of 123 patients (46%; 95% CI, 37%-54%; P = .11). In 5 patients (2 without nodal metastases), it was obvious on endosonographic imaging that the primary lung tumor invaded the mediastinum (cT4). Surgical staging was avoided due to endosonography findings in 58 of 123 patients (47%; 95% CI, 39%-56%). Sixty-five patients without evidence of mediastinal nodal metastases or mediastinal tumor invasion underwent surgical staging, showing nodal metastases in 6 additional patients. These missed mediastinal metastases (in 2 cases only micrometastases) were located in stations 4R (n=3), 5 (n=1), 6 (n=1), and 7 (n=1). The metastases in stations 5 and 6 were out of reach for endosonography. Fifty-eight patients without evidence of mediastinal nodal metastases after endosonography and surgical staging underwent thoracotomy with nodal dissection. As a result, nodal metastases were found in a further 4 patients, and 2 others were found to have mediastinal tumor invasion (Figure). At endosonography and surgical staging, a median of 3 different mediastinal nodal stations (range, 0-7) were sampled. The interobserver agreement in relation to cytological diagnosis of samples obtained with endosonography was high: k=0.97 (95% CI, 0.92-1.00).

Final Diagnoses and False-Negative Findings
The final diagnoses of the 241 patients were NSCLC (n=229; 95%; 95% CI, 91%-97%); SCLC (n=5; 2%; 95% CI, 1%-5%); other diagnoses, such as sarcoidosis (n=5; 2%; 95% CI, 1%-5%); and unknown (n=2; 1%; 95% CI, 1%-3%) (Table 1). At thoracotomy, a median of 5 lymph node stations (range, 0-10) were assessed in both study groups. At preoperative staging, nodal metastases were missed in 10 patients in the surgical staging group (stations 4L, 4R, 5, and 7) and in 4 patients in the endosonography group (stations 3A, 4L, 4R, 5, 8L, and 8R). For 8 patients (7%; 95% CI, 3%-13%) from the surgical staging group and 3 patients (2%; 95% CI, 1%-7%) from endosonography, there was no surgical verification of nodal negative findings at staging. The prevalence of mediastinal nodal metastases was 49% overall (118/241; 95% CI, 43%-56%) and similar in the surgical staging and endosonography groups: 44% (52/118; 95% CI, 35%-53%) and 54% (66/123; 95% CI, 45%-62%), respectively (P = .16). In this analysis, multiple imputation was used to assign values to missing data for mediastinal nodal status (complete cases scenario, n=120 for endosonography plus surgical staging, n=120 for surgical staging and n=120 for endosonography plus surgical staging), the sensitivity of surgical staging was 80% (41/51; 95% CI, 68%-89%) vs 94% (62/66; 95% CI, 85%-98%) for endosonography (P = .04), with corresponding NPVs of 86% (59/69; 95% CI, 75%-92%) and 93% (54/58; 95% CI, 78%-94%) (P = .26), respectively.

Nodal Metastases or Tumor Invasion
Mediastinal nodal (N2/N3) metastases were found in 41 of 118 patients (35%; 95% CI, 27%-44%) by surgical staging vs 62 of 123 patients (50%; 95% CI, 42%-59%) by the combined approach (P = .02). Additionally, tumor invasion (T4) was identified in 1 patient in the surgical staging group and 2 patients in the endosonography group (Figure). Thus, in the surgical group, 42 of 118 patients (36%; 95% CI, 28%-45%) were found to have locally advanced disease (nodal metastases and/or unforeseen direct mediastinal invasion) vs 64 of 123 patients (52%; 95% CI, 43%-61%) in the endosonography group (P = .01).

Secondary End Points
The number of unnecessary thoracotomies was 21 of 118 (18%; 95% CI, 12%-26%) in the surgical staging vs 9 of 123 (7%; 95% CI, 4%-13%) in the endosonography group (P = .02) (Table 3). There was no difference in the complication rate between the 2 groups, 7 of 118 (6%; 95% CI, 3%-12%) in the
Figure. Enrollment and Randomization of Study Patients

357 Patients assessed for eligibility

116 Excluded
98 Not eligible
54 Previous therapy for lung cancer
17 Synchronous or metachronous cancer
20 Unlikely to be staged correctly by surgery
10 Previous mediastinoscopy
4 Previous radiotherapy in neck region
6 Other reasons (eg, tracheostomy)
7 Unable to give informed consent
18 Eligible but not included
6 Declined study entry
7 Referring doctors disagreed with inclusion
5 Other reasons (1 deaf, 1 urgent thoracotomy, 1 nonadherent, 1 had no insurance, 1 logistic problems)

241 Underwent baseline assessment and randomization (stratified per center)

118 Randomized to receive surgical staging
117 Underwent surgical staging
1 Did not receive surgical staging (bone metastasis)

42 With locally advanced disease
38 N2/N3 stage
3 N2/N3 and T4 stage
1 T4 stage

75 Without locally advanced disease

58 Under went surgical staging
53 N2/N3 stage
3 N2/N3 and T4 stage
2 T4 stage

117 Underwent surgical staging
1 Did not receive surgical staging (bone metastasis)

65 Underwent thoracotomy per protocol
65 Without locally advanced disease
6 With locally advanced disease
6 N2/N3 stage
0 N2/N3 and T4 stage
0 T4 stage

70 Underwent thoracotomy per protocol
5 Did not undergo thoracotomy
1 Had endosonography
1 Had clinical deterioration
3 Refused thoracotomy

75 Without locally advanced disease

3 With locally advanced disease
2 N2/N3 stage
1 T4 stage

59 Underwent thoracotomy per protocol
58 Without locally advanced disease
59 Without locally advanced disease

16 With locally advanced disease
8 N2/N3 stage
2 N2/N3 and T4 stage
6 T4 stage

59 Without locally advanced disease

6 With locally advanced disease
3 N2/N3 stage
1 N2/N3 and T4 stage
2 T4 stage

62 Without locally advanced disease

118 Included in analysis

123 Included in analysis

N2/N3 indicates patients with locally advanced disease due to malignant unilateral (N2) or contralateral (N3) mediastinal lymph nodes. T4 indicates patients with locally advanced disease based on direct mediastinal tumor invasion. The patients with T4 because of multiple nodules in the same lobe are not shown here. In the patients without locally advanced disease, there was no evidence of either mediastinal nodal invasion or mediastinal tumor invasion. For 11 patients, there was no verification of the mediastinal nodal status (8 patients in the surgical staging group and 3 in the endosonography group). Nine of these patients did not have a thoracotomy. Two patients had a thoracotomy, but no nodal biopsies were taken. For 3 patients, there was evidence of presence of metastatic nodules in a different ipsilateral lobe (pM1) during thoracotomy (see Table 3). One of these patients also had unforeseen mediastinal nodal metastasis (pN2). Two patients underwent thoracotomy outside protocol after proven nodal invasion found by mediastinoscopy. In 1 of these patients, a bleeding complication occurred during mediastinoscopy, requiring the surgeon to convert to thoracotomy. For 1 patient in the endosonography group, the preoperative staging with endosonography and mediastinoscopy did not show locally advanced disease, but a second video bronchoscopy revealed invasion in the main carina (endoscopic T4), implying irresectability.
Table 1. Major Clinical Characteristics of Patients in Study

<table>
<thead>
<tr>
<th></th>
<th>Surgical Staging (n = 118)</th>
<th>Endosonography and Surgical Staging (n = 123)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y</td>
<td>65 (9)</td>
<td>65 (9)</td>
<td>.94</td>
</tr>
<tr>
<td>Sex, No. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>87 (74)</td>
<td>99 (80)</td>
<td>.22</td>
</tr>
<tr>
<td>Female</td>
<td>31 (26)</td>
<td>24 (20)</td>
<td></td>
</tr>
<tr>
<td>Indication for staging, No. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Known NSCLC</td>
<td>89 (75)</td>
<td>99 (80)</td>
<td>.36</td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>44 (37)</td>
<td>46 (37)</td>
<td></td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>21 (18)</td>
<td>28 (23)</td>
<td></td>
</tr>
<tr>
<td>Adenosquamous</td>
<td>2 (2)</td>
<td>3 (2)</td>
<td></td>
</tr>
<tr>
<td>Large cell carcinoma</td>
<td>3 (3)</td>
<td>6 (5)</td>
<td></td>
</tr>
<tr>
<td>Bronchoalveolar cell carcinoma</td>
<td>1 (1)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Carcinoma not further specified</td>
<td>18 (15)</td>
<td>16 (13)</td>
<td></td>
</tr>
<tr>
<td>Suspected NSCLC</td>
<td>29 (25)</td>
<td>24 (20)</td>
<td></td>
</tr>
<tr>
<td>Tumor localization, No. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left lower lobe</td>
<td>17 (14)</td>
<td>27 (22)</td>
<td>.29</td>
</tr>
<tr>
<td>Left upper lobe</td>
<td>18 (15)</td>
<td>25 (20)</td>
<td></td>
</tr>
<tr>
<td>Right upper lobe</td>
<td>30 (25)</td>
<td>28 (23)</td>
<td></td>
</tr>
<tr>
<td>Middle lobe</td>
<td>9 (8)</td>
<td>10 (8)</td>
<td></td>
</tr>
<tr>
<td>Right lower lobe</td>
<td>44 (37)</td>
<td>33 (27)</td>
<td></td>
</tr>
<tr>
<td>Tumor stage PET/CT, No. (%)</td>
<td></td>
<td></td>
<td>.47</td>
</tr>
<tr>
<td>T1</td>
<td>26 (22)</td>
<td>22 (18)</td>
<td></td>
</tr>
<tr>
<td>T2</td>
<td>66 (56)</td>
<td>80 (65)</td>
<td></td>
</tr>
<tr>
<td>T3</td>
<td>11 (9)</td>
<td>11 (9)</td>
<td></td>
</tr>
<tr>
<td>T4</td>
<td>15 (13)</td>
<td>10 (8)</td>
<td></td>
</tr>
<tr>
<td>Nodal status PET/CT, No. (%)</td>
<td></td>
<td></td>
<td>.39</td>
</tr>
<tr>
<td>N0</td>
<td>15 (13)</td>
<td>9 (7)</td>
<td></td>
</tr>
<tr>
<td>N1</td>
<td>17 (14)</td>
<td>20 (16)</td>
<td></td>
</tr>
<tr>
<td>N2</td>
<td>66 (56)</td>
<td>78 (63)</td>
<td></td>
</tr>
<tr>
<td>N3</td>
<td>20 (17)</td>
<td>16 (13)</td>
<td></td>
</tr>
<tr>
<td>Short axis of largest LN, mean (SD), mm</td>
<td>12 (5)</td>
<td>13 (4)</td>
<td>.16</td>
</tr>
<tr>
<td>ACCP classification, No. (%)</td>
<td></td>
<td></td>
<td>.70</td>
</tr>
<tr>
<td>Massive enlargement (A)</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Discrete enlargement (B)</td>
<td>73 (62)</td>
<td>76 (62)</td>
<td></td>
</tr>
<tr>
<td>Central tumor or hilar node (C)</td>
<td>35 (30)</td>
<td>33 (27)</td>
<td></td>
</tr>
<tr>
<td>Nodes &lt;10 mm (D)</td>
<td>10 (8)</td>
<td>14 (11)</td>
<td></td>
</tr>
<tr>
<td>Final histopathology data, No. (%)</td>
<td></td>
<td></td>
<td>.26</td>
</tr>
<tr>
<td>NSCLC</td>
<td>110 (93)</td>
<td>119 (97)</td>
<td></td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>47 (40)</td>
<td>51 (41)</td>
<td></td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>40 (34)</td>
<td>40 (33)</td>
<td></td>
</tr>
<tr>
<td>Adenosquamous</td>
<td>5 (4)</td>
<td>6 (5)</td>
<td></td>
</tr>
<tr>
<td>Large cell carcinoma</td>
<td>6 (5)</td>
<td>2 (2)</td>
<td></td>
</tr>
<tr>
<td>Bronchoalveolar cell carcinoma</td>
<td>0</td>
<td>1 (1)</td>
<td></td>
</tr>
<tr>
<td>Carcinoma not further specified</td>
<td>12 (10)</td>
<td>19 (15)</td>
<td></td>
</tr>
<tr>
<td>Small cell carcinoma</td>
<td>1 (1)</td>
<td>4 (3)</td>
<td></td>
</tr>
<tr>
<td>Benign lesion</td>
<td>5 (4)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>2 (2)</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ACCP, American College of Chest Physicians; LN, lymph node; NSCLC, non-small cell lung cancer; PET/CT, positron emission tomography/computed tomography.

©2010 American Medical Association. All rights reserved.

COMMENT

We have shown that commencing mediastinal nodal staging with endosonography significantly improves the detection of nodal metastases and reduces the rate of unnecessary thoracotomies by more than half compared with surgical staging alone, in patients with resectable NSCLC. This benefit is not associated with a greater rate of complications.

Imaging with CT and fluorodeoxyglucose PET is neither sensitive nor specific enough to detect the presence or absence of nodal metastasis, and therefore mediastinal tissue staging is frequently indicated in patients with nonmetastatic resectable lung cancer. There is interest in combined modality mediastinal staging for patients with resectable lung cancer because missing mediastinal nodal metastases during preoperative surgical staging results in patients needlessly undergoing thoracotomy. Because almost all mediastinal
nodes can be covered, a combined endosonography investigation could be superior to surgical staging in the detection of nodal disease. Furthermore, endosonography does not require general anesthesia, is preferred by patients, and is considered cost-effective compared with surgical staging.

It has been demonstrated previously that the addition of EUS-FNA to mediastinoscopy can increase the sensitivity of detection of mediastinal nodal disease to 93%. In that study, unsatisfactory detection of mediastinal nodal metastases from 85% to 94%, it does mean that 11 patients need to undergo mediastinoscopy to identify 1 single patient with mediastinal nodal metastasis. Therefore, it is doubtful whether all negative endosonography investigations should routinely be followed by mediastinoscopy or this strategy should be reserved for a certain subgroup.

A limitation of our study was that all investigations, including the surgical staging procedures, were performed in tertiary referral centers, potentially limiting the applicability of the study results. However, EUS-FNA and EBUS-TBNA are now incorporated as alternatives to surgical staging in international lung cancer staging guidelines. Use of the EBUS-TBNA technique is increasing, and it has been shown that EUS-FNA can be implemented successfuly.

Critical revision of the manuscript for important intellectual content: Annema, van Meerebeck, Rintoul, Doms, Deschepper, Dekkers, De Leyn, Braun, Carroll, Praet, de Ryck, Vansteenkiste, Vermaesen, Versteegh, Veselic, Nicholson, Rabe, Tournoy.

Statistical analysis: Annema, Deschepper, Dekkers, Tournoy.

Obtained funding: van Meerebeck, Rintoul, Tournoy. Administrative, technical, or material support: Annema, Rintoul, Doms, Braun, Carroll, Praet, Vansteenkiste, Vermeiren, Veselic, Versteegh, Nicholson, Rabe, Tournoy.

Study supervision: Annema, van Meerebeck, Praet, Versteegh, Rabe, Tournoy.

Financial Disclosures: Drs Annema and Rabe reported that the Department of Pulmonology at Leiden University Medical Center received support for endosonography training courses from Hitachi Medical Systems (the Netherlands/Germany) and COOK (Ireland). Dr Rintoul reported that Papworth Hospital, Cambridge, received loan EBUS equipment and support for educational endosonography courses from Olympus UK. No other disclosures were reported.

Funding/Support: Local support for data collection at Ghent University Hospital was provided by the Zorgprogramma Oncologie Gent (ZOOG) (Carla Vanendale, Heleent University Hospital). Data collection in Papworth Hospital was supported by the UK National Health Service R&D Health Technology Assessment Program (project No. 06/302/216). Drs Rintoul and Rassi were supported in part by the National Institute for Health Research Cambridge Biomedical Research Centre.

Role of the Sponsor: The funding sources had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.

Unfortunately, the entire context is not available due to the limit of characters. However, the text suggests that endosonography may be an alternative to thoracotomy for staging lung cancer, and that this was supported by evidence from various studies and clinical guidelines.